Multiple Sclerosis News Today (June 27) discusses a report issued by Spherix Global Insights, entitled "After Ocrevus approval, new MS therapies may become available, report suggests":
https://multiplesclerosisnewstoday.c...ome-available/
I'm not familiar with Spherix Global Insights but found out that it has been around for only 3 years. It seems to be an information provider for anyone interested in investing in pharmaceuticals but I'm not sure.
One of the drugs discussed, MD-1003, is also known as high-dose biotin.